In Vitro Assessment of the Allelic Variants of Cytochrome P450

被引:92
|
作者
Hiratsuka, Masahiro [1 ]
机构
[1] Tohoku Univ, Grad Sch Pharmaceut Sci, Lab Pharmacotherapy Life Style Related Dis, Aoba Ku, Sendai, Miyagi 9808578, Japan
基金
日本学术振兴会;
关键词
cytochrome P450; pharmacogenetics; genetic polymorphism; SNP; allelic variant; in vitro; kinetic parameter; POOR METABOLIZER PHENOTYPE; POTENTIALLY DEFECTIVE ALLELES; HUMAN LIVER-MICROSOMES; ESCHERICHIA-COLI; FUNCTIONAL-CHARACTERIZATION; CATALYTIC-ACTIVITY; JAPANESE POPULATION; SACCHAROMYCES-CEREVISIAE; SPECTRAL CHARACTERIZATION; S-MEPHENYTOIN;
D O I
10.2133/dmpk.DMPK-11-RV-090
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The cytochrome P450 (CYP) superfamily is one of the most important groups of enzymes involved in drug metabolism. It is responsible for the metabolism of a large number of drugs. Many CYP isoforms are expressed polymorphically, and catalytic alterations of allelic variant proteins can affect the metabolic activities of many drugs. The CYP2D6, CYP2C9, CYP2C19, and CYP2B6 genes are particularly polymorphic, whereas CYP1A1, CYP1A2, CYP2E1, and CYP3A4 are relatively well conserved without common functional polymorphisms. In vitro studies using cDNA expression systems are useful tools for evaluating functional alterations of the allelic variants of CYP, particularly for low-frequency alleles. Recombinant CYPs have been successfully expressed in bacteria, yeast, baculoviruses, and several mammalian cells. Determination of CYP variant-mediated kinetic parameters (K-m and V-max) in vitro can be useful for predicting drug dosing and clearance in humans. This review focuses on the advantages and disadvantages of the various cDNA-expression systems used to determine the kinetic parameters for CYP allelic variants, the methods for determining the kinetic parameters, and the findings of in vitro studies on highly polymorphic CYPs, including CYP2D6, CYP2C9, CYP2C19, and CYP2B6.
引用
收藏
页码:68 / 84
页数:17
相关论文
共 50 条
  • [1] In vitro assessment of human cytochrome P450
    Clarke, SE
    XENOBIOTICA, 1998, 28 (12) : 1167 - 1202
  • [2] Functional characterization of four allelic variants of human cytochrome P450 1A2
    Zhou, HJ
    Josephy, PD
    Kim, D
    Guengerich, FP
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2004, 422 (01) : 23 - 30
  • [3] Metabolism of testosterone and progesterone by cytochrome P450 2C19 allelic variants
    Takeji, Shiori
    Okada, Mai
    Hayashi, Shu
    Kanamaru, Kengo
    Uno, Yuichi
    Imaishi, Hiromasa
    Uno, Tomohide
    BIOPHARMACEUTICS & DRUG DISPOSITION, 2023, 44 (06) : 420 - 430
  • [4] In vitro assessment of cytochrome P450 inhibition and induction potential of azacitidine
    Chen, Yong
    Liu, Lisa
    Laille, Eric
    Kumar, Gondi
    Surapaneni, Sekhar
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 65 (05) : 995 - 1000
  • [5] In vitro assessment of cytochrome P450 inhibition and induction potential of azacitidine
    Yong Chen
    Lisa Liu
    Eric Laille
    Gondi Kumar
    Sekhar Surapaneni
    Cancer Chemotherapy and Pharmacology, 2010, 65 : 995 - 1000
  • [6] In Vitro Assessment of Cytochrome P450 Inhibition by Cilostazol and Its Metabolites
    Kim, Min-Jung
    Mun, Ji-Hyun
    Bae, Soo Kyung
    DRUG METABOLISM REVIEWS, 2009, 41 : 87 - 87
  • [7] In Vitro Cytochrome P450 Inhibition and Induction
    Walsky, Robert L.
    Boldt, Sherri E.
    CURRENT DRUG METABOLISM, 2008, 9 (09) : 928 - 939
  • [8] Characterization of the Inhibition of Allelic Variants of Cytochrome P450 2A6 with <it>trans</it>-Cinnamic Aldehyde
    Riehlman, Emily
    Mogstad, Emily
    Harrelson, John
    Chan, Jeannine
    FASEB JOURNAL, 2020, 34
  • [9] Characteristic of Bacillus megaterium cytochrome P450 variants
    Choi, Seon-Ju
    Yun, Chul-Ho
    DRUG METABOLISM REVIEWS, 2010, 42 : 87 - 88
  • [10] Measurement of cytochrome P450 and NADPH–cytochrome P450 reductase
    F Peter Guengerich
    Martha V Martin
    Christal D Sohl
    Qian Cheng
    Nature Protocols, 2009, 4 : 1245 - 1251